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To measure the frequency, persistence, isoform speciﬁcity, and clinical correlates of neurofascin
antibodies in patients with peripheral neuropathies.
Methods
We studied cohorts of patients with Guillain-Barre syndrome (GBS) or chronic inﬂammatory
demyelinating polyneuropathy (CIDP) (n = 59), genetic neuropathy (n = 111), and idiopathic
neuropathy (n = 43) for immunoglobulin (Ig) G and IgM responses to 3 neurofascin (NF)
isoforms (NF140, NF155, and NF186) using cell-based assays.
Results
Neurofascin antibodies were more common in patients with GBS/CIDP (14%, 8 of 59) com-
pared to genetic neuropathy controls (3%, 3 of 111, p = 0.01). Seven percent (3 of 43) of patients
with idiopathic neuropathy also had neurofascin antibodies. NF155 IgG4 antibodies were as-
sociated with CIDP refractory to IV immunoglobulin but responsive to rituximab, and some of
these patients had an acute onset resembling GBS. NF186 IgG and IgM to either isoform were
less speciﬁc. A severe form of CIDP, approaching a locked-in state, was seen in a patient with
antibodies recognizing all 3 neurofascin isoforms.
Conclusions
Neurofascin antibodies were 4 times more frequent in autoimmune neuropathy samples
compared to genetic neuropathy controls. Persistent IgG4 responses to NF155 correlated
with severe CIDP resistant to usual treatments but responsive to rituximab. IgG4 antibodies
against the common domains shared by glial and axonal isoforms may portend a particularly
severe but treatable neuropathy. The prognostic implications of neurofascin antibodies in
a subset of idiopathic neuropathy patients and transient IgM responses in GBS require
further investigation.
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Glossary
CAM = cell adhesion molecule; CIDP = chronic inﬂammatory demyelinating polyneuropathy; CMT = Charcot-Marie-Tooth;
DMEM = Dulbecco modiﬁed Eagle culture media; GBS = Guillain-Barre syndrome; IG = immunoglobulin; IVIG = IV
immunoglobulin; NF = neurofascin.
Guillain-Barre syndrome (GBS) and chronic inﬂammatory
demyelinating polyneuropathy (CIDP) are the 2 most com-
mon forms of autoimmune neuropathy. Both diseases are
highly variable in the degree that sensory and motor axons are
aﬀected, the degree of demyelination and axonal injury, and the
response to treatments. The immunologic basis of this vari-
ability is poorly understood.
Autoantibodies against membrane proteins expressed on
axons or myelinating Schwann cells have recently been
reported in some patients with CIDP or GBS. The target
antigens are concentrated at nodes of Ranvier or at paranodes
and are often cell adhesion molecules (CAMs) such as
NrCAM, gliomedin, contactin-1, neurofascin (NF) 186, and
NF155.1–7 Immunoglobulin (Ig) G4 antibodies to NF155 or
its binding partner, contactin, have been associated with severe
CIDP resistant to IV immunoglobulin (IVIG) treatment but
potentially responsive to rituximab.2,7,8
We do not yet know the full utility of neurofascin antibodies in
diagnosing autoimmune neuropathy or in guiding treatment.
NF155 is localized to paranodes9 and microvilli of myelinating
Schwann cells.10 NF186 and NF140 are localized to the axo-
lemma mature and immature nodes, respectively. All are pro-
duced from the same neurofascin gene and share some
subunits (ﬁgure 1A).7,11 We have therefore tested the fre-
quency, isoform speciﬁcity, and clinical correlates of neuro-
fascin antibodies in autoimmune, genetic, and idiopathic
neuropathy cohorts.
Methods
Standard protocol approvals, registrations,
and patient consents
Cases with GBS, CIDP, idiopathic neuropathy, and Charcot-
Marie-Tooth (CMT) neuropathy were identiﬁed from our
tissue bank at the University of Pennsylvania (Institutional
Review Board protocol 816805). An additional 76 cases with
a genetically conﬁrmed diagnosis of CMT were identiﬁed at
the National Hospital for Neurology and Neurosurgery,
Queen Square Hospital, London, as approved by the National
Hospital for Neurology and Neurosurgery Research Ethics
Committee/Central London (REC 3 09/H0716/61). Of the
76 patients (39 male and 37 female patients, mean age 46
years), 49 had demyelinating CMT and 27 had axonal CMT of
the following subtypes: CMT1A (n = 37), CMT1B (n = 1),
CMT1C (n = 1), CMT2A (n = 1), CMT2F (n = 5), CMT4B
(n = 1), CMTX1 (n = 12), and hereditary sensory neuropathy
due to SPTLC1 (n = 20) and SPTLC2 (n = 1) mutations.
Data analysis was conducted under Institutional Review Board
protocol 820981 at the University of Pennsylvania.
Neurofascin antibody detection
and characterization
Ad293 cells (Agilent Technologies, Santa Clara, CA) were plated
on poly-D-lysine–coated coverslips (Neuvitro, Vancouver,
WA) in fetal bovine serum–supplemented Dulbecco modiﬁed
Eagle culture media (DMEM) and allowed to incubate for 24
hours. Cells were transfected with the pFLAG-CMV-5a,b,c
expression vector containing mouse NF186 or the pcDNA3
expression vector containing rat NF155 (both courtesy of
Dr. Peter Brophy, University of Edinburgh). Samples reactive
against NF155 or NF186 were also tested against mouse
NF140 with a plasmid also generated by Dr. Brophy.11 Cells
were transiently transfected with the Jetprime Polyplus
Transfection Reagent (Polyplus-transfection SA, Illkirch-
Graﬀenstaden, France). Four hours after transfection, the
culture media was replaced with fresh DMEM, and cells were
then allowed to incubate for another 16 to 20 hours.
Cells were live-stained with patient sera diluted (1:100) in
DMEM for 30 minutes at 37°C, ﬁxed with 4% para-
formaldehyde, permeabilized with 0.3% Triton X-100 (Sigma
Aldrich, St. Louis, MO), and blocked with 5% normal goat
serum in PBS for 1 hour at room temperature before in-
cubation with Alexa Fluor 488–conjugated goat anti-human
IgG (H + L) (1:2,000) or IgG Fcγ (1:2,000) antibodies
(Jackson ImmunoResearch, West Grove, PA) or with Alexa
Fluor 488–conjugated goat anti-human IgM antibodies
(1:4,000) (Life Technologies, Carlsbad, CA) for 40 minutes at
room temperature. Cells were then treated for 1 hour with
polyclonal chicken anti-neurofascin primary antibodies (R&D
Systems, Minneapolis, MN), followed by Alexa Fluor 594–
conjugated goat anti-chicken IgY (H + L) antibodies for 40
minutes (1:2,000). Cells were washed with PBS between
incubations. Cells were mounted with DAPI Fluromount-G
(Southern Biotech, Birmingham, AL). Staining results were
visualized with a Leica ﬂuorescent microscope.
IgG subclasses
IgG subtypes were determined by a live staining protocol. After
blocking in 5% normal goat serum in PBS, cells were labeled
with ThermoFisher unconjugated mouse antibodies against
IgG1 (1:200), IgG2 (1:1,000), IgG3 (1:500), or IgG4 (1:75)
for 1 hour at room temperature, followed by Alexa Fluor
488–conjugated goat anti-mouse IgG (H + L) antibodies
(1:2,000) (Jackson ImmunoResearch) for 40 minutes. Cells
were then washed and stained with anti-neurofascin antibodies
as described above.
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Statistics
Frequencies of the antibodies in the diﬀerent groups were
compared with the Fisher exact test.
Results
Neurofascin antibody frequency
We screened sera from our cohorts of patients for IgG and IgM
autoantibodies to NF155 and NF186 using cell-based assays
(examples shown in ﬁgure 1B). Neurofascin antibodies were
more common in patients with GBS/CIDP (14%, 8 of 59)
compared to controls with genetic neuropathy (3%, 3 of 111,
p = 0.01). Patients with idiopathic neuropathy had in-
termediate frequency of the antibodies (7%, 3 of 43, not sig-
niﬁcantly diﬀerent from other groups). The characteristics of
antibody-positive patients with GBS and CIDP are presented
in table 1.
IgG responses to NF155
We detected NF155 IgG binding in 4 of 40 (10%) patients with
CIDP, 0 of 14 (0%) patients with GBS, and 1 of 111 (1%)
patients with CMT, indicating a low false-positive rate. None (0
of 43) of our idiopathic neuropathy patients had NF155 IgG.
The case with CMT was a 34-year-old man with a c.374T>C
(p.Leu125Pro) mutation in LITAF that was deemed to be
pathogenic because of its absence in control databases,
segregation with the disease in other aﬀected family members,
and the large physicochemical diﬀerence between leucine and
proline.
The sera with NF155 IgG were studied with subtype-speciﬁc
secondary antibodies for IgG1, IgG2, IgG3, and/or IgG4
(table 2). Our patients with CIDP with IgG to N155 all had
IgG4-predominant responses, consistent with prior reports.2,8
The single patient with CMT1 and NF155 IgG had a high titer
(1:3,200) that was predominantly IgG1; no IgG2 through
IgG4 antibodies were detected.
Our patients with CIDP with NF155 IgG antibodies share im-
portant features with previously reported patients.2 Speciﬁcally,
3 patients had high CSF protein; severe, progressive CIDP;
and poor response to IVIG treatment. After rituximab, 2 of the
3 patients showed marked improvement, and the third patient
appears to be responding 3 months after treatment. None of
them showed disabling tremor, in contrast to prior reports.
Case 3 (table 1) had coexisting NF155 IgG and anti–myelin-
associated glycoprotein antibodies (with IgMκ paraprotein),
although her clinical course was similar to that of the other
patients with NF155 IgG. Speciﬁcally, she had progressive
distal and proximal weakness with loss of ability to ambulate
over several months and then rapidly improved after rituximab,
a patternmore typical of NF155-positive patients than patients
with distal acquired demyelinating symmetric neuropathy.12
Figure 1 Neurofascin (NF) isoforms and cell-based assay
(A) NF155, NF186, and NF140 are isoforms
of neurofascin that share common extra-
cellular domains (immunoglobulin [Ig], fi-
bronectin [FN], transmembrane [TM], and
mucin), as illustrated (adapted from Zhang
et al.11 with permission). (B) HEK293 cells
were transfected to express either
NF155 or NF186, immunolabeled live
with sera, fixed, permeabilized, and
immunolabeled with a commercial
neurofascin antibody, followed by ap-
propriate secondary fluorescent anti-
bodies. This example shows human IgG
staining of cells transfected to express
NF155 for a patient with chronic in-
flammatory demyelinating poly-
neuropathy (case 4) and a control. Scale
= 10 μmol/L.
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Case 2 had a more severe phenotype than previously
reported and IgG4 recognizing NF140, NF155, and NF186.
His clinical and immunologic characteristics are detailed
below.
Case report of a patient with IgG4 to all forms
of neurofascin
Starting 1 to 2 weeks after a diarrheal illness, a 50-year-oldman
developed 2 weeks of progressive ascending weakness and









Chronic relapsing CIDP starting at age 13.
Events progress over 4–6 wk, causing inability
to walk, multifocal numbness, and areflexia.
Good recovery between events.
Prednisone (yes); IVIG and
apheresis (not clear if effective)
Mild distal symmetric polyneuropathy





At age 50, rapidly progressive weakness and
paresthesias, evolved into extraocular
weakness, ptosis, facial diplegia, dysarthria,
nearly complete ophthalmoplegia,
quadriplegia, and oscillating sympathetic
hypersensitivity with labile blood pressure.
See case report in text.





Diagnostic features of acquired,
demyelinating polyneuropathy with




At age 54, presented with 6–8 wk of progressive
numbness of all extremities, sensory ataxia, and
weakness. Became bedbound with impaired use
of the hands. Positive for anti-MAG antibodies,
initially diagnosed with DADS neuropathy before
severe progressive disability.
Prednisone (no); IVIG (no);
Rituximab and PLEX (yes)
Demyelinating neuropathy with
prolongation of all distal latencies (most




At age 39, subacute-onset progressive
numbness of the feet and then hands, then
progressive weakness. Diagnosed with optic
neuritis/papilledema, which improved with
prednisone treatment. Refractory to steroids,
IVIG, Cytoxan. Stabilized and slight
improvement after rituximab.
IVIG (no); plasmapheresis









At age 80, 6 wk of progressive numbness of
the limbs and then face, with weakness of all
extremities and face. Mild proximal and
moderate distal weakness, distal sensory loss,
and areflexia. Needed cane. Prior non-Hodgkin
lymphoma.
IVIG (yes) Severe sensory-motor neuropathy with





History of Henoch-Schonlein purpura. At age
48, had acute progressive areflexic weakness
after a cold. Sensory loss in extremities,
areflexia, and severe shoulder/back pain in
the acute phase. Became bedbound, unable to
use hands. He began improving during PLEX,
walked with a walker at 2 wk. At 11 mo, he had
normal strength and minimal sensory deficits.
A subsequent second attack occurred, but he
was lost to follow-up.
Plasmapheresis (yes) Acute neuropathy with multifocal
demyelinating features that improved
rapidly between 2 studies performed 2
weeks apart, consistent with rapidly







At age 71, developed pain and weakness
starting 5 d after a diarrheal illness in Peru;
weakness of lower then upper extremities
with no significant sensory loss; areflexia.
Became bedbound and unable to use hands
within 10 d. Clinical diagnosis of AMAN. At 14
mo, had residual moderate distal upper and
lower extremity weakness, walking with cane,
able to use buttons
IVIG for 5 d (yes but slow recovery,
likely due to axonal damage)
Severe acute motor-predominant axonal
neuropathy withmarked reduction in motor
amplitudes; 14 mo of follow-up with interval





At age 33, developed mild weakness and
tingling in toes, legs, and arms 5 d after
a GI illness. Tingling and weakness
stabilized in a couple weeks, but severe
neuropathic pain persisted. High GQ1b
IgG/IgM—117
NA Diffuse primarily demyelinating acquired
sensory-motor polyneuropathy; CSF protein
NA
Abbreviations: AMAN = acute motor axonal neuropathy; CIDP = chronic inflammatory demyelinating polyneuropathy; DADS = distal acquired demyelinating
symmetric neuropathy; GBS = Guillain-Barre syndrome; GI = gastrointestinal; Ig = immunoglobulin; IVIG = IV immunoglobulin; MAG = myelin-associated
glycoprotein; NA = not available; NF = neurofascin; PLEX = plasma exchange.
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paresthesias. On presentation, his examination was notable for
proximal and distal weakness and areﬂexia. A lumbar puncture
demonstrated mildly elevated protein (60 mg/dL) but was
otherwise unremarkable. He received 2 g/kg IVIG over 5 days
with dramatic improvement and was discharged home 1 day
after completing treatment.
Within 3 to 4 days of discharge, the ascending weakness and
paresthesias returned. On examination, he was areﬂexic and
had decreased sensation of cold, pinprick, and light touch
distally in all extremities. His strength was 2/5 to 4/5 (Medical
Research Council scale) in all upper extremity muscle groups
bilaterally, weaker proximally. Repeat CSF protein was 106
mg/dL. EMG with nerve conduction studies showed pro-
longed tibial and peroneal F waves and preserved sensory
responses with severely reduced recruitment in multiple
proximal limb muscles. He did not meet electrodiagnostic
criteria for CIDP.13 His GQ1b, HIV, and Lyme antibodies,
skeletal survey, and serum immunoﬁxation were normal.
Hewas again treated with IVIG (2 g/kg total) but continued to
decline; he had limited extraocular muscle motility, ptosis, fa-
cial diplegia, dysarthria, and 0/5 limb strength throughout with
the exception of 2/5 in ﬁnger movements and 3/5 dorsiﬂexion.
Repeat EMG with nerve conduction studies showed pro-
longed distal motor latencies and prolonged F waves di-
agnostic of CIDP and absent sensory responses. He was
treated with a third course of IVIG. One week after transfer, he
was intubated for increased secretions and worsening re-
spiratory status. At that time, he had nearly complete
ophthalmoplegia, weak cough and gag, 1/5 neck ﬂexion, and
quadriplegia. He also had oscillating sympathetic hypersensi-
tivity with labile blood pressure.
Plasmapheresis and IV solumedrol were initiated, with tran-
sient improvement. His facial strength improved to the point
that lip reading was possible, and he recovered some eye
movement.His ptosis improved, and hewas able to lift his head
oﬀ the bed. On day 36, he recovered the ability to wiggle his
ﬁngers and toes, but he soon worsened. Cyclophosphamide
(750 mg/m2) was initiated on day 52 for the ﬁrst of 3 monthly
doses. At this point, he was communicating by protruding his
tongue for “yes.” A second course of IV solumedrol and
a second round of plasmapheresis were initiated, and his ex-
amination improved. He was able to open his eyes, to move his
eyes in all directions, and to move his lips to mouth words.
However, he developed aspiration pneumonia, and he again
became essentially “locked in,” unable to move. A third round
of plasmapheresis was initiated, and he received his second
dose ofmonthly cyclophosphamide.On day 86, he received his
ﬁrst of 3 weekly doses of rituximab (375 mg/m2). On day 104,
his ophthalmoparesis began improving, and he was able to
move his jaw. Over the course of the next 2 weeks, he was able
to open his eyes, stick out his tongue, and nod his head. He was
transferred to a long-term ventilator facility.
Ten months after his initial presentation, he was transferred to
acute rehabilitation, decannulated, and gradually advanced to
a normal diet. At the last follow-up 19 months after symptom
onset, he was able to ambulate with bilateral ankle-foot
Table 2 IgG1 through IgG4 subclasses of IgG-positive patients
Case Diagnosis Isoform reactivity and titer IgG subtype (if IgG present and strong enough to subtype)
1 CIDP NF155 IgG and IgM 1:200 Predominantly IgG4; also detected IgG1 and IgG2
2 CIDP NF155 IgG 1:800; NF186 IgG 1:1,600 Predominantly IgG4; also detected IgG1 and IgG2
3 CIDP NF155 IgG 1:1,600 Predominantly IgG4; also detected minimal IgG1 and IgG2
4 CIDP NF155 IgG 1:3,200 Detected IgG1, IgG2, and IgG4
5 CIDP NF186 IgM 1:1,600 —
6 GBS NF155 IgM 1:3,200 —
7 AMAN NF186 IgM 1:1,600 —
8 GBS NF186 IgM 1:3,200 —
9 Idiopathic neuropathy NF155 IgM 1:400 —
10 Idiopathic Neuropathy NF186 IgG 1:800 Detected minimal IgG4
11 Idiopathic neuropathy NF186 IgM 1:800 —
12 CMT NF155 IgM 1:200 —
13 CMT NF155 IgG 1:3,200 Predominantly IgG1, No IgG2, IgG3, or IgG4 detected
14 CMT NF155 IgM 1:100 —
Abbreviations: AMAN = acute motor axonal neuropathy; CIDP = chronic inflammatory demyelinating polyneuropathy; CMT = Charcot-Marie-Tooth; GBS =
Guillain-Barre syndrome; Ig = immunoglobulin; NF = neurofascin.
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orthotics, drive, and grip utensils. There was still severe
weakness of all ankle and foot movements, as well as moderate
weakness of intrinsic hand muscles.
IgG responses to NF186
In addition to case 2, a low-titer NF186 IgG response (without
coexisting NF155 reactivity) was detected in 1 patient with
idiopathic neuropathy. No other cases of CIDP,GBS (0 of 14),
or CMT (0 of 111) were associated with isolated reactivity to
NF186.
IgM responses to NF155 or NF186
IgM responses to NF155 or NF186 were detected in 5 of 59
(8%) patients with autoimmune neuropathy: 2 with CIDP
(cases 1 and 5), 1 with acute inﬂammatory demyelinating
polyneuropathy (case 6), 1 with acute motor axonal neurop-
athy (case 7), and 1 with features of CIDP and GBS (case 8).
One patient with CIDP (case 1) had IgM against NF155 with
a coexisting IgG4 response to NF155. IgM responses to
NF186 or NF155 were also detected in 2 of 111 (2%) patients
with CMT and 2 of 43 (5%) patients with idiopathic neu-
ropathy. The 2 cases with CMT included a 78-year-old man
with CMT1A and a relatively mild phenotype as deﬁned by
a CMT examination score of 7 and CMT neuropathy score of
12 and a patient with progressive neuropathy from age 3
without a deﬁnitely identiﬁed mutation.
Epitope mapping of neurofascin IgG responses
NF155, NF186, and NF140 share some subunits in their ex-
tracellular domains (ﬁgure 1A). To determine the target
epitopes of our NF155 or NF186 IgG–positive samples, we
used cell-based assays for each of the 3 isoforms (ﬁgure 2).
Isoform speciﬁcity and titers are summarized in table 2. Three
of 4 sera with NF155 IgG responses did not recognize NF186
or NF140. These patients most likely had antibodies against
epitopes involving the third ﬁbronectin-like domain, which is
the only domain expressed inNF155 that is not present in both
NF186 andNF140. Case 2, however, had strong IgG reactivity
against all 3 neurofascin isoforms, indicating that at least 1
target epitope was in a domain that was shared by all 3 neu-
rofascin isoforms. Because all of the domains of NF140 are also
present in NF155 and NF186, a response to NF140 is suﬃ-
cient to explain his response to NF155 and NF186, but this
does not exclude the possibility that his antibodies also rec-
ognize domains speciﬁc to NF155 or NF186.
Persistence of responses over time
When possible, we analyzed follow-up samples fromCIDP and
neurofascin reactivity. Follow-up samples from 2 patients with
NF155 IgG were studied. Case 2 provided samples during
initial onset, 2 months later (during severe symptoms), and 19
months later, after the patient had signiﬁcant recovery. The
ﬁrst 2 samples showed strong NF140, NF155, and NF186 IgG
reactivity, whereas the ﬁnal sample was negative for all neu-
rofascin isoforms. In contrast, case 1, who had relapsing/
remitting CIDP, had 2 samples collected 2 years apart, both of
which were positive (she had had no attacks in years).
Follow-up samples were also obtained for 3 patients with IgM
responses but no IgG responses. Case 5, who had CIDP and
responded to IVIG treatment, continued to have IgM anti-
bodies against NF186 over the course of 8 months, during
which time 4 samples were collected at 2- to 4-month intervals
and the patient was still experiencing weakness but much im-
proved symptoms as a result of regular IVIG infusions. Cases 6
and 7 had GBS and acute motor axonal neuropathy, re-
spectively. Case 6 had IgM against NF155, and case 7 had IgM
against NF186 during acute illness. Follow-up samples, after
acute symptoms had subsided, were negative for IgM or IgG
antibodies. Case 6 subsequently experienced a relapse of his
neuropathy but was lost to follow-up.
Discussion
We comprehensively examined the frequency, clinical corre-
lates, isoform speciﬁcity, and persistence of neurofascin anti-
bodies in patients with diverse kinds of neuropathy. Our study
supports the speciﬁc association of NF155 IgG4 with severe
CIDP refractory to IVIG but often responsive to rituximab.
These responses were speciﬁc to the NF155 isoform for most
cases. Transient responses, often IgM, occurred in some patients
with GBS. In addition, we found a higher frequency of neuro-
fascin responses in idiopathic neuropathy compared to genetic
neuropathy. Finally, we have reported a patient with incredibly
severe but treatable neuropathy associated with autoimmunity
to the common domains shared by all neurofascin isoforms.
Neurofascin antibodies were ﬁrst reported in the context of
multiple sclerosis14 and later in GBS.15 Subsequent reports
have describedNF155 and/or NF186 IgM or IgG responses in
1% to 18% of patients with GBS and CIDP, depending on the
diagnosis and type of antibody.1 An association of NF155 IgG
with CIDP particularly became clearer in subsequent reports,4
followed by the association of NF155 IgG4 with CIDP re-
sistant to IVIG treatment and responsive to rituximab in small
groups of patients.2,8,16 Most recently, a study of 246 patients
with CIDP found 5 patients (2%) with IgG4-predominant
responses to the common epitopes of NF140, NF186, and
NF155.17 These patients generally had subacute onset,
prominent sensory ataxia, and sometimes cranial nerve in-
volvement.While these patients had some similarities to case 2,
none were as severely aﬀected. As with our case, clinical re-
mission correlated with resolution of the antibody response.
NF155 IgG4 was found in 10% of our patients with CIDP, so
screening appropriate patients may be clinically useful. One
case had coexisting myelin-associated glycoprotein antibodies
and met criteria for distal acquired demyelinating symmetric
neuropathy but was otherwise similar to our other NF155 IgG-
positive cases.
Transient IgM responses to neurofascin occurred in some of
our patients with GBS, and some of our patients with NF155
IgG4 initially presented with an acute-onset neuropathy
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resembling GBS. Because immunoglobulins are thought to be
progressively expressed by maturing B cells in a speciﬁc order
(IgM→IgG3→IgG1→IgG2→IgG4),18 it is likely that patients
who have an IgG4 against NF155 started with an IgM against
NF155. IgM responses to NF155 or NF186 were, however,
found in several diﬀerent groups of patients (those with idio-
pathic neuropathy, CMT, CIDP, and GBS), so they do not
invariably progress to IgG4 responses. Additional studies are
needed to determine whether patients with GBS with neuro-
fascin IgM are at higher risk of progressing toCIDP or whether
IgM antibodies contribute to pathogenesis.
In most cases, antibody responses were speciﬁc to either
NF155 or NF186, consistent with prior studies showing that
Figure 2 Isoform specificity of neurofascin (NF) responses
HEK293 cells were transfected to ex-
press NF155 (A), NF186 (B), or NF140 (C),
immunolabeled live with sera, fixed,
permeabilized, and immunolabeled
with a commercial neurofascin anti-
body, followed by appropriate second-
ary fluorescent antibodies. Most cases
with neurofascin antibodies, like case 4,
were specific to NF155 or NF186. Case 2
is so far unique in recognizing all 3 iso-
forms. See text. Scale 10 μmol/L.
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NF155 antibodies recognize the third and fourth ﬁbronectin-
like domains4 and that most NF155 antibodies recognize
a glycosylated epitope in the ﬁrst through fourth ﬁbronectin-
like domains.19 Case 2 had reactivity to an epitope shared by all
3 isoforms. This “pan-neurofascin” immune response could
potentially aﬀect both NF186 (localized to nodes) and NF155
(mostly localized to paranodes) and may account for the se-
vere phenotype observed. Other patients with CIDP and
antibodies to NF155 have been disabled and unable to am-
bulate, but the nearly locked-in state of our patient is un-
precedented. It would be informative to study other patients
with extremely severe CIDP for this antibody response. Ad-
ditional studies may determine whether the disappearance of
the neurofascin antibody response, as in this case, is a reliable
biomarker of clinical CIDP remission. Even in the setting of
profound disability, immune therapy and patience may lead to
a signiﬁcant recovery.
The NF155 IgG responses we observed were IgG4 pre-
dominant, matching prior reports. IgG4 antibodies have
unique properties, including being functionally monovalent as
a result of hemi-antibody exchange, having very high aﬃnities,
and not ﬁxing complement.20 IgG4 antibodies to CAMs like
neurofascinsmay act by disrupting their interactions with other
CAMs.21 Testing for IgG4 to NF155, not just IgG to NF155,
may increase the speciﬁcity of a positive ﬁnding for treatment-
resistant CIDP.
By some estimates, almost half of patients with chronic pro-
gressive neuropathy are idiopathic, having no identiﬁable
cause.7,22 It is possible that some patients with idiopathic
neuropathy may have an autoimmune cause even though they
lack the distinctive clinical and electrophysiologic ﬁndings of
GBS or CIDP. The possibility of an increased frequency of
neurofascin antibodies in idiopathic compared to genetic
neuropathy therefore requires further investigation.
Our work supports the concept that autoantibodies to pe-
ripheral nerve proteins such as neurofascins may deﬁne par-
ticular phenotypes and predict response to treatment. Our
work also demonstrates that diﬀerent types of antibody
responses to the same antigen (IgM vs IgG, persistent vs
transient) or antibody responses to diﬀerent parts of the same
protein (NF155-speciﬁc domains vs core neurofascin
domains) have diﬀerent prognostic implications.
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